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RESUMO – Introdução: A biopsia do gânglio sentinela é um procedimento genericamente aceite no estdiamento do melanoma. O 
valor prognóstico desta técnica parece ser mais relevante nos melanomas de espessura intermédia (1-4mm) do que nos melanomas 
espessos (>4mm). Objectivo: Avaliar o valor prognóstico do estado do gânglio sentinela em doentes com melanoma espesso. Doentes 
e Métodos: A sobrevivência livre de doença e a sobrevivência global foram estimadas pelo método de Kaplan-Meier e por um modelo 
de regressão de Cox numa amostra de doentes com melanoma espesso. Resultados: Foram incluídos 43 doentes (52.2% do sexo mas-
culino) com uma média etária de 63,9 anos. A biopsia do gânglio sentinela foi positiva em 20 casos (46,5%). O tempo médio de segui-
mento foi de 40 meses. Os doentes em que não foram encontradas metástases no gânglio sentinela tiveram uma sobrevivência livre de 
doença aos 5 anos significativamente maior do que o grupo de doentes com gânglio sentinela positivo (63% versus 19%, p<0.05). A 
sobrevivência global aos 5 anos foi tendencialmente mais baixa em doentes com gânglio sentinela positivo (52% versus 79%), embora 
sem significado estatístico. Conclusão: O estado do gânglio sentinela não teve influência estatística na sobrevivência global dos doen-
tes da nossa série de melanomas espessos, provavelmente devido ao risco elevado de metastização por via hemática. Porém, a biopsia 
do gânglio sentinela forneceu informação prognóstica relevante, uma vez que teve clara influência na sobrevivência livre de doença.
PALAVRAS-CHAVE – Biópsia do Gânglio Sentinela; Melanoma; Neoplasias da Pele; Prognóstico; Taxa de Sobrevida.
Sentinel Lymph Node Biopsy in Thick Melanoma: 
A Single-Centre Retrospective Clinical Study
ABSTRACT – Background: Sentinel lymph node biopsy is widely accepted in the staging of melanoma. The prognostic value of this 
technique seems to be greater in intermediate-thickness melanoma (1-4 mm) than in thick melanoma (>4 mm). Objective: To assess 
the prognostic value of sentinel node status in patients with thick melanoma. Patients and Methods: The disease-free survival and the 
overall survival were estimated using Kaplan-Meier curves and a Cox regression model in a sample of patients with thick melanoma. 
Results: Forty-three patients were included (52.2% male) with a mean age of 63.9 years. Sentinel node biopsy was positive in 20 patients 
(46.5%). Mean follow-up was 40 months. Patients without sentinel node metastases had a 5-year disease-free survival rate significantly 
higher than those with positive sentinel node (63% versus 19%, p < 0.05). The 5-year overall survival rate was tendentiously lower in 
patients with positive sentinel node (52% versus 79%), lacking statistical significance. Conclusion: The sentinel node status was not able 
to predict the overall survival in our series of thick melanomas, probably due to the high risk of hematic spread. However, sentinel lymph 
node biopsy provided important prognostic information, since the sentinel lymph node status influenced the disease-free survival.
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INTRODUCTION
Sentinel lymph node biopsy (SNB) is a safe and minimally 
invasive technique that provides relevant information about 
the sentinel lymph node status, which is one of the most im-
portant prognostic factors for patients with localized cuta-
neous melanoma.1
Although the prognostic value of this technique is largely 
established in intermediate thickness melanoma (1 to 4mm), 
there is still some controversy regarding its efficiency and relia-
bility in thick melanoma (> 4mm). This is mainly due to the fact 
that this subset of patients has a high risk of hematic spread of 
the disease regardless the sentinel lymph node status.  
Data about the prognostic impact of sentinel lymph node 
status in thick melanoma are conflicting in several studies. In 
the latest report of the MSLT-I trial (Multicenter Selective Lym-
phadenectomy Trial), consisting of a 10-year review, Morton 
et al2 observed that the SNB-based staging in primary thick 
melanoma provided important prognostic information and 
was correlated with a significant increase in disease-free sur-
vival (DFS), although this was not true for overall survival (OS). 
Fairbairn et al achieved similar results in their study.3 Several 
other authors4-12 have been successful in correlating the SNB-
-based staging with improved DFS and OS, advocating its use 
in this subset of patients. The results presented by Vermeeren et 
al13 suggest that the only relevant prognostic factor regarding 
patients with thick melanoma is SNB and this procedure can 
be used to stratify patients according to the risk of recurrence. 
Conversely, Rhodes14 and Oliveira Filho et al,15 stated that SNB 
status does not contribute with relevant prognostic information 
in patients with thick melanoma and, therefore, SNB should not 
be recommended due to the lack of prognostic information. 
The aim of this retrospective clinical study was to assess the 
prognostic value of sentinel lymph node status in patients with 
thick melanoma and to determine its usefulness as a staging 
procedure. 
MATERIALS AND METHODS
This study reviewed medical files of patients with cutaneous 
melanoma (thickness higher than 4.0 mm) in whom SNB was 
successfully performed in the Department of Dermatology, 
Coimbra University Hospital Center, Coimbra, Portugal, be-
tween January 2004 and December 2010. The data were col-
lected during 2015.
The sentinel lymph node identification was performed by 
lymphoscintigraphy. The radiotracer used was 99mTc-albumin 
nanocolloid that was injected intradermally in 4 different points 
around the primary tumor or around the scar of the excisional 
biopsy. This injection occurred 18-24 hours prior to surgery. 
The imaging was taken by a gamma camera and the loca-
lization of the sentinel lymph node was marked on the skin. 
A gamma probe was used to detect the sentinel lymph node 
during surgery. The first lymph node receiving the radiotracer 
in a given basin were considered the sentinel node, as well as 
those nodes which had at least 10% of the radioactive count of 
the hottest sentinel node detected intraoperatively in that basin. 
The sentinel nodes were formalin fixed, paraffin embedded 
and systematically sectioned under a “breadloafing” techni-
que. Classical stain with hematoxylin-eosin and immunostains 
with HMB-45 and S-100 were performed. 
The patients were assigned to two study groups: group A 
(patients with positive SNB), and group B (patients with nega-
tive SNB).
In both groups the following variables were studied: de-
mographic variables (age and gender), variables related to 
melanoma and its progression (melanoma subtype, thick-
ness, presence of ulceration, location, average follow-up time, 
tumor recurrence, DFS, melanoma-related death and OS) and 
sentinel lymph node status. Mitotic rate was not included, since 
the patients were collected before 2010, previous to the inclu-
sion of the mitotic rate in the staging system of the American 
Joint Committee on Cancer.
Descriptive statistic measures were applied to all the study 
variables: mean, standard deviation, median and interquartile 
intervals (percentile 25 to percentile 75).
Variables were compared recurring to methods of inferen-
tial statistics, using chi-square test for nominal variables and 
Pearson’s correlation test for quantitative variables. 
DFS and OS were calculated and interpreted by the me-
thod of Kaplan-Meier, which produced survival curves. Hazard 
ratios (HR) were determined from a Cox regression analysis, 
which was also used to access the effect of the different varia-
bles in DFS and OS. 
A p value under 0.05 was defined as statistically significant. 
Statistical analysis was performed using the software pro-
gram IBM® SPSS® Statistics 20.
RESULTS
A total of 43 patients with thick melanoma were included: 
21 women (48.8%) and 22 men (51.2%), with a mean age 
of 63.9 years. SNB was positive in 20 (46.5%) patients (group 
A) and negative in 23 (53.5%) patients (group B). The mean 
follow-up was 40 months.
The characteristics of both groups are summarized in 
Table 1.
Fifteen patients (35%) suffered melanoma-related death, 
with 9 patients belonging to group A (45%) and 6 belonging 
to group B (26%). No significant differences were observed 
between both groups respecting the risk of suffer an event of 
melanoma-related death.
A total of 22 patients (51%) suffered disease recurrence, 
with 14 patients (70%) belonging to group A and 8 patients 
(35%) belonging to group B. Despite this tendency, no statisti-
cally significant differences were found. 
Overall, DFS (Fig. 1) was longer in group B (average of 
55 months, 95% confidence interval: 41 to 68 months), when 
compared with group A (average of 28 months, 95% confiden-
ce interval: 15 to 41 months), with a 5-year disease-free survi-
val rate of 63% in group B and 19% in group A. This difference 
between the two groups was statistically significant (p=0.02 by 
log rank test). The hazard ratio was 2.7 with 95% confidence 
interval of 1.1 to 6.6 (p<0.05). 
Overall survival (Fig. 2) was higher in group B (average of 
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Table 1 - Characteristics of patients with thick melanoma according with sentinel lymph node status.
TOTAL Positive SNB(Group A)
Negative SNB
(Group B P value
Patients, n (%) 43 20 (46.5) 23 (53.5)
Age (years)
•	 Mean	+	SD
•	 Median
•	 Interquartile	Range	(25-75)
64 ± 16
69
23
62 ± 15
67
25
66 ±	17
69
19
NS
Gender, M/F 22 / 21 12 / 8 10 / 13 NS
Melanoma Location, n (%)
•	 Head/Neck
•	 Trunk
•	 Upper	Limb
•	 Lower	Limb
4 (9)
13 (30)
4 (9)
22 (51)
0
7	(35)
2 (10)
11 (55)
4	(17)
6 (26)
2 (9)
11 (48)
NS
Melanoma Type, n (%)
•	 Superficial	Spreading	Melanoma
•	 Nodular	Melanoma
•	 Acral-Lentiginous	Melanoma
•	 Other	Types
1 (2)
13 (30)
18 (42)
11 (26)
0
6 (30)
9 (45)
5 (25)
1 (4)
7	(30)
9 (39)
6 (26)
NS
Tumor Thickness (mm)
•	 Mean	+	SD
•	 Median
•	 Interquartile	Range	(25-75)
7.47	± 4
6.62
3
7.89	±4
7
2
7.1	± 3
6
3
<0,001
Ulceration, nr (%)
•	 Yes
•	 No
•	 Unknown
28 (65)
11 (26)
4 (9)
14	(70)
4 (20)
2 (10)
14 (61)
7	(30)
2 (9)
NS
Disease Recurrence, n (%)
•	 Yes
•	 No
22 (51)
21 (49)
14	(70)
6 (30)
8 (35)
15 (65)
NS
Follow-up Time (months)
•	 Mean	+	Stand.	deviation
•	 Median
•	 Interquartile	Range	(25-75)
40 ± 26
34
45
33 ± 24
27
33
44 ±	27
48
51
NS
Melanoma-related death, n (%) 15 (35) 9 (45) 6 (26) NS
NS	–	Non	significant;	SD	–	Standard	deviation.
Figure 1 - Disease-free	survival	in	patients	with	thick	melanoma	ac-
cording	with	sentinel	lymph	node	status.	
Figure 2 - Overall	survival	in	patients	with	thick	melanoma	according	
with	sentinel	lymph	node	status.		
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72 months, 95% confidence interval: 57 to 86 months) when 
compared with group A (average of 50 months, 95% confi-
dence interval: 35 to 65 months). The hazard ratio for death 
in patients with positive sentinel lymph node was 2.2, with a 
95% confidence interval of 0.8-6.1, which was non-significant 
(p=0.146). The 5-year survival rate corresponded to 79% 
in group B versus 52% in group A (p=0.132, log rank test). 
However, using Wilcoxon’s generalized test, we were able to 
achieve statistical significance (p=0.041).
The only other variable which significantly influenced DFS 
in thick melanoma was melanoma thickness (p≤0.001). This 
variable showed also significant influence in the risk of mela-
noma-related death (p≤0.001).
DISCUSSION
According with the results reported by Morton et al in the 
MSTL-1 trial,2 there was a clear disparity in terms of DFS but 
not OS between patients with thick melanoma having a po-
sitive or negative SNB result. Nevertheless, this study strati-
fied patients in two different groups, matching the tumor’s 
Breslow thickness: patients with intermediate thickness mela-
noma (1.20 to 3.50mm) and patients with thick melanoma 
(over 3.5mm). This is conflicting with the AJCC staging, which 
considers the cutoff of 4.0mm in the definition of thick me-
lanoma. This stratification may create some concerns when 
comparing different studies. We should point out that several 
authors4-12 stated that sentinel lymph node status predicts DFS 
as well as OS in patients with thick melanoma. 
According to our results, lymph node metastases were 
identified by SNB in 46.5% of the patients, a finding con-
sistent with other studies.8,16 DFS was longer in patients with 
negative SNB, when compared with patients with positive SNB 
but there was no significant difference in terms of OS in the 
two groups. The impossibility to obtain significant differen-
ces in terms of OS can be explained by the morphology of 
the survival curves (“banana shaped” curves). These curves 
represent a survival superiority in the SNB negative group in 
early follow-up period (which may explain the significant Wi-
lcoxon test, that focus on early events). Over time, proba-
bly due to the high hematic metastases rate, characteristic 
of thick melanomas, this survival superiority vanishes, and 
mortality rates become similar in both groups. Thus, the fact 
that no survival differences were found in both groups in the 
later follow-up might explain the non-significance of the Log 
Rank test, which is focused on later events. Despite the shorter 
follow-up period, these results are consistent with those obtai-
ned by Morton et al1 and Fairbarn et al.3
Concerning the prognostic value of other variables, only 
melanoma thickness had a significant influence in DFS and 
in OS. These results are similar to those obtained by Fairbarn 
et al,3 in which tumor thickness was the only significant prog-
nostic factor that influences OS in thick melanoma. 
In conclusion, despite its inability to predict overall survi-
val, SNB is a recommended procedure in patients with thick 
melanoma, as it provides an inestimable value in terms of 
staging and prognosis.
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